Shares of the thinly traded nanocap biotech TRACON Pharmaceuticals Inc (NASDAQ: TCON) were rallying Thursday.
Tracon, which specializes in novel therapeutics for cancer, said it has dosed the first patient in a U.S. Phase 1 first-in-human clinical trial of I-Mab's proprietary CD73 antibody TJD5, also known as TJ004309, in patients with advanced solid tumors.
TJD5 is from Chinese biopharma stable and it is being co-developed through a corporate collaboration between Tracon and I-Mab that was signed in November 2018.
TJD5 will be dosed in the Phase 1 trial both as a single agent and in combination with Tecentriq, Roche Holdings AG Basel ADR (OTC: RHHBY)'s PD-L1 immunotherapy, Tracon said.
The study will evaluate the safety and tolerability of TJD5 in a bid to finalize the recommended doses for further clinical studies of its efficacy and safety as a single agent and in combination with a standard dose of Tecentriq in patients with advanced or metastatic cancer who are intolerant of all available therapies.
Why It's Important
"We will continue to work with I-Mab to optimize the clinical development of TJD5, an antibody with global best-in-class potential," Tracon CEO Charles Theuer said in a statement.
Incidentally, TRACON had to shelve a late-stage study of a pipeline asset in April, which sent its shares down by about 50% in a single session. The stock hasn't recovered much since then.
Treatment resistance to PD-1/PD-L1 is seen as a challenge for several cancer types. The combination of TJD5 and Tecentriq will provide a novel treatment option to address the unmet medical needs, according to I-Mab.
Tracon shares were trading higher by 8.8% at 48 cents at the time of publication Thursday.
Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates
See more from Benzinga
- The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster
- The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings
- The Week Ahead In Biotech: Pending Clinical Readouts In Focus
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.